UBS Group’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-9,303
| Closed | -$36.9K | – | 10574 |
|
|
2025
Q3 | $36.9K | Buy |
9,303
+7,135
| +329% | +$48.6K | ﹤0.01% | 7768 |
|
|
2025
Q2 | $26K | Sell |
2,168
-1,970
| -48% | -$24.4K | ﹤0.01% | 8272 |
|
|
2025
Q1 | $57K | Sell |
4,138
-5,537
| -57% | -$79.5K | ﹤0.01% | 7479 |
|
|
2024
Q4 | $138K | Buy |
+9,675
| New | +$159K | ﹤0.01% | 6681 |
|
|
2024
Q2 | – | Sell |
-512
| Closed | -$11.7K | – | 9582 |
|
|
2024
Q1 | $11.7K | Buy |
+512
| New | +$11K | ﹤0.01% | 7166 |
|
|
2023
Q3 | – | Sell |
-167
| Closed | -$2.81K | – | 9518 |
|
|
2023
Q2 | $2.81K | Sell |
167
-244
| -59% | -$4.2K | ﹤0.01% | 7689 |
|
|
2023
Q1 | $6.4K | Buy |
+411
| New | +$7.98K | ﹤0.01% | 7924 |
|
|
2022
Q4 | – | Sell |
-307
| Closed | -$5K | – | 10765 |
|
|
2022
Q3 | $5K | Buy |
307
+278
| +959% | +$6.09K | ﹤0.01% | 9175 |
|
|
2022
Q2 | $0 | Sell |
29
-201
| -87% | -$4.88K | ﹤0.01% | 10376 |
|
|
2022
Q1 | $8K | Sell |
230
-446
| -66% | -$13.3K | ﹤0.01% | 8657 |
|
|
2021
Q4 | $28K | Buy |
676
+224
| +50% | +$14.5K | ﹤0.01% | 7452 |
|
|
2021
Q3 | $41K | Buy |
452
+14
| +3% | +$1.24K | ﹤0.01% | 6494 |
|
|
2021
Q2 | $32K | Buy |
438
+38
| +10% | +$1.77K | ﹤0.01% | 6848 |
|
|
2021
Q1 | $15K | Sell |
400
-205
| -34% | -$10.3K | ﹤0.01% | 7622 |
|
|
2020
Q4 | $24K | Sell |
605
-663
| -52% | -$17.2K | ﹤0.01% | 6801 |
|
|
2020
Q3 | $29K | Buy |
1,268
+189
| +18% | +$4.88K | ﹤0.01% | 6015 |
|
|
2020
Q2 | $30K | Sell |
1,079
-141
| -12% | -$4.15K | ﹤0.01% | 6260 |
|
|
2020
Q1 | $31K | Sell |
1,220
-423
| -26% | -$15.6K | ﹤0.01% | 6182 |
|
|
2019
Q4 | $71K | Sell |
1,643
-1,182
| -42% | -$24.8K | ﹤0.01% | 6173 |
|
|
2019
Q3 | $27K | Buy |
2,825
+2,821
| +70,525% | +$40.5K | ﹤0.01% | 6543 |
|
|
2019
Q2 | $0 | Sell |
4
-301
| -99% | -$5.37K | ﹤0.01% | 7882 |
|
|
2019
Q1 | $6K | Sell |
305
-60,511
| -99% | -$1.2M | ﹤0.01% | 7071 |
|
|
2018
Q4 | $976K | Buy |
60,816
+60,647
| +35,886% | +$2.85M | ﹤0.01% | 3711 |
|
|
2018
Q3 | $16K | Sell |
169
-248
| -59% | -$29.5K | ﹤0.01% | 6921 |
|
|
2018
Q2 | $67K | Buy |
417
+280
| +204% | +$47.2K | ﹤0.01% | 5759 |
|
|
2018
Q1 | $22K | Sell |
137
-102
| -43% | -$12.4K | ﹤0.01% | 6344 |
|
|
2017
Q4 | $25K | Sell |
239
-64
| -21% | -$6.87K | ﹤0.01% | 6376 |
|
|
2017
Q3 | $40K | Buy |
303
+116
| +62% | +$14.2K | ﹤0.01% | 5950 |
|
|
2017
Q2 | $26K | Sell |
187
-148
| -44% | -$17.8K | ﹤0.01% | 6101 |
|
|
2017
Q1 | $40K | Buy |
335
+114
| +52% | +$13.5K | ﹤0.01% | 5677 |
|
|
2016
Q4 | $29K | Buy |
221
+54
| +32% | +$13.6K | ﹤0.01% | 6256 |
|
|
2016
Q3 | $43K | Buy |
+167
| New | +$20.5K | ﹤0.01% | 5631 |
|
Other funds holding CLSD
UBS Group's CLSD Position: Q4 2025 in Review
UBS Group sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 9,303 shares — an estimated $36.9K sold.
UBS Group first reported a position in CLSD in Q3 2016 and held it in 32 quarters. The position peaked at $976K in Q4 2018. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- UBS Group reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 9,303 Clearside Biomedical shares in Q4 2025, an estimated $36.9K.
- UBS Group first reported a position in Clearside Biomedical in Q3 2016 and held it in 32 quarters.
- UBS Group's Clearside Biomedical position peaked at $976K in Q4 2018.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.